Most Recent
Samsung Bioepis can't get indemnity costs from Janssen Biotech after it surrendered patents for Crohn’s disease drug Stelara and filed a fresh case based on new patents for the drug.
Pharmaceuticals giant Lundbeck has succeeded in overturning IP Australia’s decision granting Novartis unit Sandoz a licence to sell a generic version of top-selling antidepressant Lexapro.
Medical device supplier Medtronic has been socked with a $22 million penalty after it supplied non-compliant bone graft kits to hospitals, in what is the largest penalty under the Therapeutics Good Act.
The privacy regulator was alerted to hundreds of data breaches in the first half of 2024, the highest number in three and a half years, a new report shows.
Expect more cybersecurity class actions following the introduction of a new statutory tort for serious invasions of privacy, experts on both sides of the bar table told Lawyerly.
Mesoblast has agreed to settle a shareholder class action centred on statements to the market about its Remestemcel-L treatment, resolving claims it misrepresented the efficacy of the therapy for COVID-19 patients.
A Sydney law firm has filed a class action accusing private equity-owned medical device maker Exactech of supplying faulty joint implants that were subject to deterioration due to a packaging defect, caused serious medical complications in patients.
A class action on behalf of 700 patients alleging assisted reproduction provider Monash IVF destroyed potentially viable embryos in a faulty genetic screening program has settled for $56 million.
A GlaxoSmithKline unit has defeated Nova Pharmaceuticals' bid to trade mark 'Novadart' for a generic version of the British company's market-leading drug prostate drug 'Avodart', with a delegate finding the mark would cause consumer confusion.
US-based Dana-Farber Cancer Institute has succeeded in patenting a patient-specific method for developing cancer vaccines using genome sequencing.